Novel Staphylococcus sp. specific bacteriophage OPT-SX11 and antibacterial composition comprising the same
The bacteriophage OPT-SX11 specifically targets and kills antibiotic-resistant Staphylococcus aureus, offering a novel antibiotic alternative that overcomes resistance issues and enhances treatment options for mastitis in dairy cows.
Patent Information
- Application Number
- KR1020230184240
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-12-18
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2043-12-18
AI Technical Summary
The increasing prevalence of antibiotic-resistant Staphylococcus aureus, particularly in dairy cows, poses a significant threat to farm ecosystems and public health, complicating the management and treatment of mastitis and leading to the need for alternative treatments.
Development of a bacteriophage, OPT-SX11, with a specific nucleotide sequence (SEQ ID NO. 1) that selectively targets and kills Staphylococcus aureus, including antibiotic-resistant strains, and is incorporated into antibiotic, feed additive, disinfectant, and pharmaceutical compositions.
OPT-SX11 effectively kills Staphylococcus aureus without inducing drug resistance, providing a novel antibiotic alternative with a longer product life cycle and addressing issues of antibiotic residues and broad host ranges.
Smart Images

Figure 112023141573426-PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a novel Staphylococcus-specific bacteriophage OPT-SX11 and an antimicrobial composition containing the same. Background Technology
[0003] Staphylococcus sp. is classified into coagulase-positive and coagulase-negative strains based on its ability to produce coagulase. Staphylococcus causes various diseases, including suppurative diseases, wound infections, osteoarthritis, pneumonia, and sepsis, and is also one of the major causative agents of mastitis in dairy cows. Staphylococcus generally exhibits strong resistance to environmental factors; in particular, the enterotoxin produced by Staphylococcus aureus is not destroyed even after heating at 100°C for 30 minutes, posing a significant problem for our society. It can spread nationwide in a short period of time via food distribution networks, passing through various stages such as the production and manufacturing processes of food (milk). Once transmitted to humans, Staphylococcus can serve as another vector for further transmission to humans or animals (dairy cows).
[0004] Antibiotics are used to suppress bacteria causing mastitis in dairy cows, and antibiotic-resistant bacteria resulting from this use are being detected. In particular, methicillin-resistant Staphylococcus aureus (MRSA) possesses resistance to beta-lactam antibiotics; since this resistance can be transmitted between bacteria and is highly contagious, infections occur among dairy cows. While MRSA was previously perceived as primarily a problem for humans, it is now reported to be distributed in livestock (dairy cows), mainly in Europe. Consequently, the distribution of MRSA in livestock poses a significant threat to farm ecosystems and public health. When MRSA acts as the causative agent of mastitis in dairy cows, it reduces farm productivity and simultaneously forms a reservoir of highly resistant bacteria capable of transmission to humans and animals. Furthermore, MRSA can develop resistance to common antibiotics used to treat mastitis in dairy cows, making the management and treatment of mastitis more difficult and necessitating antibiotic alternatives.
[0005] Dairy bovine mastitis is a disease in which inflammation occurs in mammary gland tissue due to microbial infection, chemical irritation, or injury, and it is classified into clinical and subclinical forms. In a 2021 survey by the Animal and Plant Quarantine Agency, clinical mastitis was identified in 6.1% and subclinical mastitis in 13.7% of 12,574 dairy cows. The main causative agents were identified as Staphylococcus (24.7%), Staphylococcus aureus (16.8%), Escherichia coli (9.0%), Streptococcus (6.2%), and Enterococcus (5.9%), while the remainder accounted for less than 5%. Although antibiotic resistance varies among the causative agents, the rate of antibiotic resistance is showing a continuously increasing trend.
[0006] Bacteriophages are bacteria-specific viruses that infect specific bacteria, inhibit their growth, and destroy them. After infection, they multiply within the bacteria, and their progeny bacteriophages possess the ability to kill the bacteria by destroying their cell walls. Bacteriophages exhibit high bacterial specificity; this means they kill only specific bacteria and do not affect other bacterial species. Recently, due to the international preference for eco-friendly methods, interest in bacteriophages is higher than ever. In particular, there is a need to develop technologies for bacteriophages with specific lytic activity against Staphylococcus aureus, the causative agent of mastitis in dairy cows, as well as for their applications.
[0007] Accordingly, the inventors isolated a bacteriophage having lytic activity specific to Staphylococcus aureus and analyzed the morphological and genetic characteristics of the isolated bacteriophage. By confirming that the bacteriophage can selectively kill Staphylococcus aureus and possesses physicochemical stability, the present invention was completed. Prior art literature
[0009] (Patent Document 0001) KR 10-2018-0074584 A1(Patent Document 0002) KR 10-2014-0140402 A1(Patent Document 0003) KR 10-0781669 B1 The problem to be solved
[0010] The objective of the present invention is to provide a bacteriophage having a killing ability specific to Staphylococcus aureus.
[0011] Another objective of the present invention is to provide an antibiotic composition, a feed additive composition, a feed, a disinfectant, or a cleaning agent comprising the above-mentioned bacteriophage.
[0012] Another objective of the present invention is to provide a method for preventing or treating an infectious disease caused by Staphylococcus aureus, comprising the step of administering the bacteriophage to an individual.
[0013] Another objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of infectious diseases caused by Staphylococcus aureus. means of solving the problem
[0015] To achieve the above objective, the present invention provides a bacteriophage OPT-SX11 composed of a nucleotide sequence represented by SEQ ID NO. 1, which has a killing ability specific to Staphylococcus aureus.
[0016] In addition, the present invention provides an antibiotic composition comprising the bacteriophage OPT-SX11.
[0017] In addition, the present invention provides a feed additive composition comprising the bacteriophage OPT-SX11.
[0018] In addition, the present invention provides a feed comprising the above-mentioned feed additive composition.
[0019] In addition, the present invention provides a disinfectant comprising the bacteriophage OPT-SX11.
[0020] In addition, the present invention provides a washing agent comprising the bacteriophage OPT-SX11.
[0021] In addition, the present invention provides a method for preventing or treating an infectious disease caused by Staphylococcus aureus, comprising the step of administering the bacteriophage OPT-SX11 to an individual.
[0022] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of infectious diseases caused by Staphylococcus aureus, comprising the bacteriophage OPT-SX11 as an active ingredient. Effects of the invention
[0024] The present invention relates to a novel Staphylococcus-specific bacteriophage OPT-SX11 and an antimicrobial composition containing the same. The bacteriophage OPT-SX11 of the present invention has the advantage of specifically infecting Staphylococcus aureus, exhibiting excellent lytic activity, and being resistant to physicochemical stimuli. As such, it can solve problems such as antibiotic-resistant bacteria caused by the misuse of antibiotics, antibiotic residues in food, and broad host ranges, and can be utilized in various fields, including antibiotic compositions, feed additive compositions, animal feed, disinfectants, cleaning agents, and for the prevention or treatment of infectious diseases caused by Staphylococcus aureus. Brief explanation of the drawing
[0026] Figure 1 is a figure showing the gene map of the bacteriophage OPT-SX11 of the present invention. Figure 2 is a figure showing the results of analyzing the morphology of the bacteriophage OPT-SX11 of the present invention using an electron microscope. Figure 3 is a figure showing the results of confirming the bacterial killing efficacy of the bacteriophage OPT-SX11 of the present invention. Figure 4 is a figure showing the results of confirming the pH stability of the bacteriophage OPT-SX11 of the present invention. Figure 5 is a figure showing the results of confirming the thermal stability of the bacteriophage OPT-SX11 of the present invention. Specific details for implementing the invention
[0027] The present invention will be described in detail below.
[0029] The present invention provides a bacteriophage OPT-SX11 composed of a nucleotide sequence represented by SEQ ID NO. 1, having a killing ability specific to Staphylococcus aureus.
[0030] In the present invention, the term "bacteriophage" refers to a bacterium-specific virus that infects a specific bacterium and inhibits and suppresses the growth of said bacterium, and means a virus comprising single or double-stranded DNA or RNA as genetic material.
[0031] The staphylococci exhibiting specific killing ability in the present invention are Staphylococcus aureus or coagulase-negative staphylococci, and include, but are not limited to, antibiotic-resistant staphylococci.
[0032] The total gene size of the bacteriophage OPT-SX11 of the present invention is 140,468 bp, the GC content is 30.1%, and the ORF is 220. The bacteriophage OPT-SX11 is 300 nm to 320 nm in size and belongs to the Myoviridae family, having an icosahedral head and a contractile tail. In addition, the bacteriophage OPT-SX11 has the ability to kill Staphylococcus aureus through excellent susceptibility to Staphylococcus aureus.
[0033] The bacteriophage OPT-SX11 of the present invention may include the nucleotide sequence represented by SEQ ID NO. 1 as the whole or part of the entire gene. Additionally, the bacteriophage OPT-SX11 of the present invention may consist of the nucleotide sequence represented by SEQ ID NO. 1 and a functional equivalent of said nucleotide sequence. The functional equivalent refers to a sequence that, as a result of modification or substitution of the nucleotide sequence, has sequence homology of at least 70%, preferably 80%, more preferably 90%, and even more preferably 95% or more with respect to the nucleotide sequence represented by SEQ ID NO. 1, and exhibits substantially the same physiological activity as the nucleotide sequence represented by SEQ ID NO. 1.
[0034] The above-described Staphylococcus-specific lytic activity enables the bacteriophage OPT-SX11 of the present invention to be applied to compositions for the prevention and treatment of infectious diseases caused by Staphylococcus, and to various products containing said bacteriophage OPT-SX11 as an active ingredient.
[0035] The bacteriophage OPT-SX11 of the present invention is a bacteriophage isolated after culturing a sample collected from a wastewater treatment plant together with Staphylococcus aureus. The inventors named it bacteriophage OPT-SX11 and deposited it with the Korean Culture Collection of Microorganisms on June 23, 2023, under accession number KCCM13361P.
[0037] In addition, the present invention provides an antibiotic composition comprising the bacteriophage OPT-SX11.
[0038] In addition to the present invention, the present invention provides an antibiotic composition comprising the bacteriophage OPT-SX11.
[0039] In the present invention, the term "antibiotic composition" refers to a preparation capable of killing bacteria when provided to an individual in the form of a drug, and collectively refers to preservatives, disinfectants, antibiotics, and antimicrobial agents.
[0040] Since the bacteriophage OPT-SX11 of the present invention has very high specificity against Staphylococcus aureus compared to existing antibiotics, it can kill only specific pathogens without killing beneficial bacteria and does not induce drug resistance or intolerance, so it can be used as a novel antibiotic with a longer life cycle compared to existing antibiotics.
[0042] In addition, the present invention provides a feed additive composition comprising the bacteriophage OPT-SX11.
[0043] In the present invention, the term "antibiotic composition" refers to a preparation capable of killing bacteria when provided to an individual in the form of a drug, and collectively refers to preservatives, disinfectants, antibiotics, and antimicrobial agents.
[0044] Since the bacteriophage OPT-SX11 of the present invention has very high specificity against Staphylococcus aureus compared to existing antibiotics, it can kill only specific pathogens without killing beneficial bacteria and does not induce drug resistance or resistance, so it can be used as a novel antibiotic with a longer product life cycle compared to existing antibiotics.
[0046] In addition, the present invention provides a feed comprising the above-mentioned feed additive composition.
[0047] The feed of the present invention may be prepared by separately manufacturing bacteriophages in the form of feed additives and mixing them into the feed, or by directly adding them during feed production. The bacteriophages in the feed of the present invention may be in a liquid or dried state, preferably in the form of dried powder. Drying methods may include air drying, natural drying, spray drying, and freeze-drying, but are not limited thereto. The bacteriophages of the present invention may be mixed in powder form at a component ratio of 0.05 to 10 weight%, preferably 0.1 to 2 weight%, of the weight of the feed. In addition, the feed may additionally include conventional additives that can enhance the shelf life of the feed, in addition to the bacteriophages of the present invention.
[0048] Other non-pathogenic microorganisms may be additionally added to the feed additive composition of the present invention. Microorganisms that may be added may be selected from a group consisting of: Bacillus subtilis, which can produce proteolytic enzymes, lipolytic enzymes, and sugar-converting enzymes; Lactobacillus sp., which has physiological activity and organic matter decomposition ability under anaerobic conditions such as the stomach of a cow; filamentous fungi such as Aspergillus oryzae, which show effects of increasing the body weight of livestock, increasing milk production, and increasing the digestibility and absorption rate of feed; and yeasts such as Saccharomyces cerevisiae.
[0049] The feed containing the bacteriophage OPT-SX11 of the present invention includes, for plant sources, grains, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, oilseed oils, grain by-products, etc., and for animal sources, proteins, inorganic substances, mineral substances, single-cell proteins, zooplankton, leftover food, etc., but is not limited thereto.
[0050] The feed additive composition of the present invention may include binders, emulsifiers, preservatives, etc. added to prevent quality degradation, and may include amino acid preparations, vitamin preparations, enzyme preparations, probiotics, flavoring agents, non-protein nitrogen compounds, silicate preparations, buffers, coloring agents, extractants, oligosaccharides, etc. added to the feed to increase utility, and may additionally include feed mixing agents, etc.
[0052] In addition, the present invention provides a disinfectant comprising the bacteriophage OPT-SX11.
[0053] The disinfectant comprising the bacteriophage OPT-SX11 of the present invention, which has a specific killing ability against Staphylococcus aureus, can be usefully used as a disinfectant for hospitals and public health to prevent hospital infections, and can be used as a general household disinfectant, a disinfectant for food and cooking areas and facilities, and for disinfecting various growth supplies such as buildings (poultry farms, livestock barns, etc.), livestock, drinking water, bedding, egg trays, transport vehicles, and tableware.
[0055] In addition, the present invention provides a washing agent comprising the bacteriophage OPT-SX11.
[0056] Since the bacteriophage OPT-SX11 of the present invention has a specific killing ability against Staphylococcus aureus, it can also be used to wash the skin surface or various parts of the body of an individual who has been exposed to or is likely to be exposed to Staphylococcus aureus.
[0058] In addition, the present invention provides a method for preventing or treating an infectious disease caused by Staphylococcus aureus, comprising the step of administering the bacteriophage OPT-SX11 to an individual.
[0059] Since the bacteriophage OPT-SX11 of the present invention has a specific killing ability against Staphylococcus aureus, it can be used for the prevention or treatment of infectious diseases caused by Staphylococcus aureus. More specifically, since the bacteriophage OPT-SX11 of the present invention has a specific killing ability against Staphylococcus aureus, it can be used for the prevention or treatment of infectious diseases caused by said Staphylococcus aureus.
[0060] In the present invention, infectious diseases caused by Staphylococcus include, but are not limited to, skin infections, bedsores, keratitis, otitis media, endocarditis, pneumonia, bacteremia, meningitis, brain abscess, otitis externa, osteomyelitis, wound infections, sepsis, urinary tract infections, chronic respiratory infections, pancreatic cystic fibrosis, intra-abdominal infections, osteoarthritis, and cellulitis.
[0061] In the present invention, the term "individual" refers to any individual capable of developing an infectious disease caused by Staphylococcus aureus, and includes, but is not limited to, mammals, livestock, or poultry excluding humans.
[0062] In the present invention, the term "livestock" refers to a concept of useful animals that have been domesticated and improved by humans and live together with humans, including, but not limited to, pigs, cattle, chickens, horses, ducks, or dogs.
[0063] In the present invention, the term "poultry" is a general term for animals belonging to the bird family among livestock, including, for example, chickens, ducks, pheasants, quails, ostriches, geese, or turkeys, but is not limited thereto.
[0064] In the method of the present invention, the bacteriophage OPT-SX11 or composition may be administered to animals in the form of a pharmaceutical preparation, or by mixing it into livestock feed or drinking water and feeding it.
[0065] In the method of the present invention, the administration route of the bacteriophage OPT-SX11 or the composition may be administered via various oral or parenteral routes as long as it can reach the target tissue, and specifically, it may be administered in a conventional manner through the oral cavity, rectum, local area, intravenous area, abdominal cavity, intramuscular area, intra-arterial area, transdermal area, nasal area, inhalation, etc.
[0066] It is obvious to those skilled in the art that the appropriate total daily dose of the bacteriophage OPT-SX11 administered in the method of the present invention can be determined by the treating physician within the scope of proper medical judgment. It is desirable to apply the specific therapeutically effective dose for a specific individual differently depending on various factors and similar factors well known in the pharmaceutical field, including the type and degree of response to be achieved, the patient's age, weight, general health condition, gender and diet, time of administration, route of administration and secretion rate of the composition, duration of treatment, and drugs used together or simultaneously with the specific composition.
[0068] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of infectious diseases caused by Staphylococcus aureus, comprising the bacteriophage OPT-SX11 as an active ingredient.
[0069] The bacteriophage OPT-SX11 of the present invention has fewer problems regarding the emergence of resistant bacteria than general antimicrobial agents and exhibits lytic activity specific to Staphylococcus aureus, so it can be used for the prevention or treatment of infectious diseases caused by Staphylococcus aureus.
[0070] In the present invention, the term "treatment" means prevention of disease caused by Staphylococcus aureus; inhibition of disease caused by Staphylococcus aureus; and alleviation of disease caused by Staphylococcus aureus.
[0071] As the bacteriophage included in the composition of the present invention can kill Staphylococcus aureus as described above, it is effective in treating various diseases caused by said Staphylococcus aureus, such as suppurative arthritis, suppurative osteomyelitis, wound infection, osteoarthritis, pneumonia, sepsis, mastitis, skin infection, otitis media, wound infection, bacteremia, endocarditis, empyema, osteomyelitis, infectious arthritis, and spondylomyelitis. In order to obtain additional therapeutic effects, the composition for this purpose may additionally include a component that has already been proven to have antibacterial activity against these strains.
[0072] Additionally, the composition of the present invention may further include a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier included in the composition of the present invention is one that is commonly used in formulations and includes, but is not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
[0073] The pharmaceutical composition of the present invention may additionally include a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, etc., in addition to the above components.
[0074] In the method of the present invention, the administration route of the bacteriophage OPT-SX11 or the composition may be administered via various oral or parenteral routes as long as it can reach the target tissue, and specifically, it may be administered in a conventional manner through the oral cavity, rectum, local area, intravenous area, abdominal cavity, intramuscular area, intra-arterial area, transdermal area, nasal area, inhalation, etc.
[0075] Suitable application, spraying, and dosages of the pharmaceutical composition of the present invention vary depending on factors such as the method of formulation, mode of administration, patient's age, body weight, sex, severity of disease symptoms, diet, time of administration, route of administration, rate of excretion, and response sensitivity, and a moderately skilled physician can easily determine and prescribe a dosage effective for the desired treatment. Generally, the pharmaceutical composition of the present invention is 1×10 3 Up to 1×10 10 It may contain pfu / ml of bacteriophages.
[0076] The pharmaceutical composition of the present invention may be prepared in a unit dose form or contained in a multi-dose container by being formulated using a pharmaceutically acceptable carrier or excipient according to a method that can be easily carried out by a person skilled in the art to which the present invention belongs. In this case, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granule, tablet, or capsule, and may additionally include a dispersant or a stabilizer.
[0078] Terms not otherwise defined in this specification have the meanings commonly used in the technical field to which the present invention belongs.
[0079] The present invention will be explained in detail below through examples and formulation examples. However, the following examples and formulation examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples and formulation examples.
[0081] <Example 1> Isolation and Culture of Novel Bacteriophages
[0082] <1-1> Screening and Isolation of Bacteriophages
[0083] Experiments were conducted to isolate bacteriophages specific to Staphylococcus aureus.
[0084] Specifically, the target bacterium, Staphylococcus xylosus KCCM 40887, was obtained from the Korean Culture Collection Center. Samples collected from the Byeongcheon Wastewater Treatment Plant in Chungcheongnam-do were cultured overnight with the target bacterium using shaking. The culture medium was centrifuged at 3,000 rpm for 20 minutes, and the supernatant was filtered using a filter with a pore size of 0.2 μm. Bacteriophages specific to Staphylococcus were then selected through lysis plate analysis using the obtained filtrate.
[0085] To screen for bacteriophages, 200 μL of pre-cultured target bacteria was specifically taken and placed in a sterile tube. 3 mL of TSB top agar [(tryptone 17.0 g, soytone 3.0 g, dextrose 2.5 g, sodium chloride 5.0 g, Dipotassium phosphate 2.5 g / L) + 0.6 agar] was added and mixed thoroughly, then superimposed onto a pre-prepared 2% TSA plate. After incubating at room temperature for 30 minutes, 10 μL of the prepared sample filtrate was spotted onto each plate, incubated at room temperature for 30 minutes, and then incubated at 35°C for 24 hours to check for the presence of bacteriophages. The soft agar overlay method was used to isolate the phages in purity from the samples in which the presence of bacteriophages was confirmed. Samples confirmed to contain bacteriophages were appropriately diluted with saline, and 100 μL of the sample dilution from each dilution step was taken and mixed with 200 μL of the target bacterial culture. Then, 3 mL of 0.6% TSB top agar was added and mixed thoroughly. The mixture was then superimposed onto pre-prepared 2% TSA plates and left to stand, followed by incubation at 35°C for 24 hours. After confirming the lysis spots formed on each cultured plate, selected ones were suspended in 400 μL of SM buffer (NaCl 5.8 g / L; MgSO4 7H2O 2 g / L; 1M Tris-HCl (pH 7.5) 50 mL) and left at room temperature for 4 hours. 100 μL of this bacteriophage solution was mixed with 500 μL of 0.6% TSB top agar and bacterial culture solution, then dispensed onto a 150 mm diameter TSA plate and supernatant was incubated at 35°C until complete lysis occurred. After incubation was finished, 15 mL of SM buffer was added to the TSA plate and the bacteriophage solution was recovered while stirring slowly at room temperature for 4 hours. The solution was then centrifuged at 3,000 rpm for 20 minutes, and only the supernatant was collected and filtered through a 0.2 μm filter to recover the final bacteriophage solution.
[0087] <1-2> Mass Culture and Purification of Bacteriophages
[0088] In order to mass culture the Staphylococcus-specific bacteriophage identified in Example 1-1 above, the final bacteriophage culture solution recovered in Example 1-1 was 1.0 X 10 8 1.0 X 10⁶ pre-cultured S. xylosus diluted to PFU / mL 8 The mixture was mixed to achieve a CFU / mL and MOI (Multiplicity of Infection) of 0.1 and cultured overnight at 100 rpm at 35°C. After the culture was finished, the entire volume of the culture medium was centrifuged at 3,000 rpm for 30 minutes to obtain the supernatant, which was then filtered through a 0.2 μm filter to recover the final bacteriophage culture medium.
[0089] The isolated bacteriophage was named “Bacteriophage OPT-SX11” and deposited with the Korean Culture Center of Microorganisms (Seoul, Korea) on June 23, 2023, and was assigned the accession number KCCM13361P.
[0091] <Example 2> Whole-Genome Analysis of Bacteriophage OPT-SX11
[0092] An experiment was conducted to analyze the entire gene of bacteriophage OPT-SX11.
[0093] Specifically, genetic analysis was performed using the Phage DNA Isolation Kit (NORGEN). 10 μL (20 units) of Norgen's RNase-Free DNase I was added to the bacteriophage OPT-SX11 culture medium and reacted at room temperature for 15 minutes, followed by incubation for 5 minutes in a heating block preheated to 75°C. 500 μL of Lysis Buffer B was added to the reaction mixture and mixed well; subsequently, 4 μL of Preoteinase K was added, and the mixture was incubated using a heating block at 55°C for 15 minutes and 65°C for 15 minutes. 320 μL of isopropanol was added to the reaction mixture and mixed thoroughly. A spin column was placed on a collection tube, and 650 μL of the reaction mixture was dispensed into the spin column. After centrifugation at 6,000 rpm for 1 minute, the solution passing from the spin column into the collection tube was discarded. 400 μL of wash solution A was added to the DNA-adsorbed spin column, and after centrifugation at 6,000 rpm for 1 minute, the wash solution passing through the tube was discarded. This step was repeated 3 times, followed by idle spinning at 13,000 rpm for 2 minutes. The spin column was transferred to an elution tube, 75 μL of elution buffer B was added, and DNA was extracted by centrifugation at 6,000 rpm for 1 minute. After measuring the DNA concentration, gene sequencing was performed using MiSeq for whole-genome analysis (Senigen, Korea).
[0094] The gene map of bacteriophage OPT-SX11 obtained from DNA sequencing results is shown in Figure 1. As shown in Figure 1, the total gene size of bacteriophage OPT-SX11 is 140,468 bp, the GC content is 30.1%, and 220 ORFs were identified. The total gene sequence of the analyzed bacteriophage OPT-SX11 is indicated as Sequence No. 1.
[0096] <Example 3> Morphological characteristics of bacteriophage OPT-SX11
[0097] Experiments were conducted to confirm the morphological characteristics of bacteriophage OPT-SX11.
[0098] Specifically, the culture medium was diluted in a 0.01% gelatin solution and fixed with a 2.5% glutaraldehyde solution. This was applied dropwise to a carbon-coated mica plate (ca. 2.5 x 2.5 mm), allowed to acclimatize for 10 minutes, and then washed with sterile distilled water. The plate was placed on a copper grid, stained in 2% uranyl acetate for 30 to 60 seconds, dried, and then observed using a transmission electron microscope (Tecnai G2 Spirit Twin, Bio-Transmission electron microscope, 120 kV, 120,000–400,000).
[0099] As a result, as shown in Figure 2, it was confirmed that bacteriophage OPT-SX11 has a size of 240 nm to 308.5 ± 5 nm and belongs to the Myoviridae family, having an icosahedral head and a contractile tail.
[0101] <Example 4> Investigation of the infectivity and killing ability of bacteriophage OPT-SX11 against Staphylococcus
[0102] <4-1> Confirmation of Staphylococcus-specific Infectivity of Bacteriophage OPT-SX11
[0103] In order to confirm whether bacteriophage OPT-SX11 exhibits lytic activity against Staphylococcus aureus and various bacteria, infectivity was confirmed through a spot assay using strains isolated and held by Optipharm Co., Ltd. and strains obtained from the Microbial Support Center.
[0104] Target bacteria name lytic activity confirmation bacterial count / total bacterial count Sensitivity ratio Staphylococcus aureus 100 / 100 100% Methicillin-resistant- Staphylococcus aureus 7 / 7 100% Staphylococcus borealis 3 / 3 100% Staphylococcus chromogenes 3 / 3 100% Staphylococcus epidermidis 3 / 3 100% Staphylococcus haemolyticus 3 / 3 100% Staphylococcus saprophyticus 3 / 3 100% Staphylococcus sciuri 1 / 3 33% Staphylococcus simulans 2 / 3 66% Staphylococcus xylosus 3 / 3 100% Total 128 / 131 99%
[0105] Gram-positive bacteria Species Strain OPT-SX11 phage infection Bacillus cereus ATCC 11778 Non-susceptible Streptococcus iniae KCTC 3657 Non-susceptible Enterococcus faecalis Wild type Non-susceptible Enterococcus faecium Wild type Non-susceptible Streptococcus uberis KVCC-BA0001861 Non-susceptible Streptococcus dysgalactiae KVCC-BA0001419 Non-susceptible Gram-negative bacteria Species Strain OPT-SX11 phage infection Salmonella Typhimurium ATCC 14028 Non-susceptible Escherichia coli KCTC 1039 Non-susceptible
[0106] As a result, as shown in Table 1, bacteriophage OPT-SX11 demonstrated 99% (128 out of 131) lytic activity against 131 species of Staphylococcus sp. isolated from dairy farms, confirming that it possesses excellent lytic activity against Staphylococcus. In addition, as a result of conducting susceptibility studies on various species of Staphylococcus, it was confirmed that bacteriophage OPT-SX11 exhibited infectivity against various species of Staphylococcus, indicating a wide range of lytic activity.
[0107] In addition, as shown in Table 2, when a spot assay was performed to confirm activity against gram-positive and gram-negative bacteria other than Staphylococcus aureus, it failed to inhibit the gram-positive and gram-negative bacteria used in the experiment.
[0109] <4-2> Confirmation of Staphylococcus-killing ability of bacteriophage OPT-SX11
[0110] The killing ability of bacteriophage OPT-SX11 against Staphylococcus xylosus (KCCM 40887) was analyzed.
[0111] Specifically, 10 mL of bacterial culture medium was prepared so that the absorbance at 600 nm was approximately 0.5. Bacteriophage OPT-SX11 was added to the bacterial culture medium at MOIs of 1, 0.1, and 0.01, respectively. The experiment was conducted using an experimental group inoculated only with bacteria as a control group, and the culture was incubated at 35°C for 6 hours, with absorbance measured at 600 nm at 1-hour intervals.
[0112] As a result, as shown in Figure 3, in the control group without the addition of bacteriophage OPT-SX11, the absorbance at 600 nm after 6 hours was 3.6, confirming that bacteria had proliferated. On the other hand, in the experimental group with the addition of bacteriophage OPT-SX11, the absorbance values at 600 nm after 6 hours compared to the initial absorbance were MOI 1, 0.1, and 0.01, with values of 0.076, 0.055, and 0.876, respectively, indicating that bacteria were effectively killed.
[0113] The above results indicate that bacteriophage OPT-SX11 has excellent killing ability against Staphylococcus xylosus.
[0115] <Example 5> Investigation of pH stability of bacteriophage OPT-SX11
[0116] Experiments were conducted to confirm the pH stability of bacteriophage OPT-SX11.
[0117] Specifically, to confirm stability with respect to pH, the number of bacteriophages was measured across various pH ranges (pH 2, 3, 4, 5, 6, 7, 8, 9, 10, 11). Sodium acetate buffer, sodium phosphate buffer, and Tris-HCl were prepared according to each pH and dispensed into 990 μL volumes. Bacteriophage OPT-SX11 culture medium was 1.0 x 10⁶ 8 After preparing the culture solution to a concentration of PFU / mL, 10 μL aliquots were taken and added to each buffer solution prepared according to pH, and the mixture was left at room temperature for 1 hour. After leaving the mixture, each reaction solution was serially diluted, and the titer was measured using the soft agar overlay method.
[0118] As a result, as shown in Figure 4, it was confirmed that the bacteriophage OPT-SX11 of the present invention is stable for 1 hour in the pH range of 4 to 11.
[0119] The above results indicate that the bacteriophage OPT-SX11 of the present invention is a bacteriophage with excellent pH stability.
[0121] <Example 6> Investigation of Thermal Stability of Bacteriophage OPT-SX11
[0122] Experiments were conducted to verify the thermal stability of bacteriophage OPT-SX11.
[0123] Specifically, to verify thermal stability, the number of bacteriophages was measured after being left for a certain period at various temperature ranges (35, 40, 50, 60, 70℃). More specifically, bacteriophage OPT-SX11 culture medium (1.0 X 10⁶ 8 1 mL of (PFU / mL) was dispensed into a sterile tube and left at each temperature for 10, 30, and 60 minutes. After leaving, each reaction solution was serially diluted, and the titer was measured using the soft agar overlay method.
[0124] As a result, as shown in FIG. 5, the bacteriophage OPT-SX11 of the present invention is stable for 60 minutes in the range of 40°C to 50°C, and at 60°C, when 60 minutes have elapsed, the number of phages is 10 6 10 in PFU / mL 3 It was confirmed that it decreased by PFU / mL.
[0125] The above results indicate that the bacteriophage OPT-SX11 of the present invention is a bacteriophage with excellent heat resistance.
[0127] From the above experiments, it was confirmed that bacteriophage OPT-SX11 specifically infects Staphylococcus aureus, exhibits excellent lytic activity, and possesses the advantage of being resistant to physicochemical stimuli. Furthermore, since the bacteriophage OPT-SX11 of the present invention does not infect other bacteria, it has the advantage of resolving problems such as antibiotic-resistant bacteria resulting from the misuse of antibiotics, antibiotic residues in food, and broad host ranges. Therefore, the bacteriophage OPT-SX11 of the present invention can be used in various fields, such as the prevention or treatment of infectious diseases caused by Staphylococcus aureus, antibiotic compositions, feed additive compositions, animal feed, disinfectants, or cleaning agents.
[0129] Although the present invention has been described as a preferred embodiment mentioned above, various modifications and variations are possible without departing from the essence and scope of the invention. Furthermore, the appended claims include such modifications and variations that fall within the essence of the invention.
[0131] The following describes an example of a pharmaceutical composition for the prevention or treatment of infectious diseases comprising the bacteriophage OPT-SX11 of the present invention, but this is not intended to limit the present invention and is merely to provide a specific description thereof.
[0133] <Preparation Example 1> Preparation of a pharmaceutical product
[0134] <1-1> Preparation of Injectables
[0135] Bacteriophage OPT-SX11 1.0x10 7 PFU / mL
[0136] Appropriate amount of sterile distilled water for injection
[0137] Appropriate amount of pH adjuster
[0138] It is prepared according to the conventional method of manufacturing injectables with the above-mentioned ingredient content per ampoule (2 mL).
[0140] <1-2> Preparation of Liquid Formulations
[0141] Bacteriophage OPT-SX11 1.0x10 7 PFU / mL
[0142] 20 g sugar
[0143] 20 g isomerized sugar
[0144] Appropriate amount of lemon flavor
[0145] Purified water was added to make the total volume 1,000 mL. The above ingredients were mixed according to the standard method for preparing liquid preparations, then filled into a brown bottle and sterilized to prepare the liquid preparation.
[0147] <1-3> Preparation of Tablets
[0148] Bacteriophage OPT-SX11 1.0x10 7 PFU / mL
[0149] 100 mg of corn starch
[0150] 100 mg of lactose
[0151] Magnesium stearate 2 mg
[0152] After mixing the above ingredients, tablets are manufactured by compressing them according to the conventional method of manufacturing tablets.
[0154] Depository Name: Korean Culture Collection Center (KCCM) Trustee Number: KCCM13361P Date of Deposit: 2023-06-23
Claims
Claim 1 Bacteriophage OPT-SX11, having a specific killing ability against Staphylococcus aureus, consisting of the nucleotide sequence represented by SEQ ID NO. 1 and deposited under accession ID KCCM13361P. Claim 2 delete Claim 3 In paragraph 1, the bacteriophage is a myovirium ( Myoviridae Bacteriophage OPT-SX11, characterized by belonging to ). Claim 4 In claim 1, the bacteriophage OPT-SX11 is characterized by having a total genome size of 140,468 bp. Claim 5 In claim 1, the bacteriophage OPT-SX11 is characterized by having a size of 300 nm to 320 nm. Claim 6 Antibiotic composition comprising the bacteriophage OPT-SX11 of claim 1. Claim 7 A feed additive composition comprising the bacteriophage OPT-SX11 of claim 1. Claim 8 Feed comprising the feed additive composition of claim 7. Claim 9 A disinfectant comprising the bacteriophage OPT-SX11 of claim 1. Claim 10 A cleaning agent comprising the bacteriophage OPT-SX11 of claim 1. Claim 11 delete Claim 12 delete Claim 13 delete
